Research Article
BibTex RIS Cite

Brain Metastases, Large Cell Neuroendocrine Carcinomas and Prognosis

Year 2023, Volume: 50 Issue: 1, 30 - 36, 19.03.2023
https://doi.org/10.5798/dicletip.1266706

Abstract

Objective: Pulmonary large cell neuroendocrine carcinomas (LNECs) are not common but brain metastases are common in LNEC patients. Because of their rarity, there are no randomized controlled trials on optimal treatment. Generally available data are based on case reports and retrospective studies. For this reason, we retrospectively analyzed patients with LNEC that we followed up for brain metastases to contribute to the literature.
Methods: Between 2009 and 2020, 38 patients with brain metastases diagnosed with LNEC in our center were reviewed retrospectively.
Results: 38 patients were evaluated. The mean survival time was 5.17 months (95% confidence interval (CI) : 3.17-7.13). In multivariate analysis showed us that; shorter overal survival is associated with age (p=0.001), uncontrol of primary cancer (p=0.014), presence of metachronous metastases (p=0.003), poor Eastern Cooperative Oncology Group (ECOG) performance score (p=0.025), and high uric acid level (p=0.001) and high lactate dehydrogenase (LDH) levels (p=0.009).
Conclusion: LNECs are rare but aggressive cancers. LNECs often metastasize to the brain. According to our study, high LDH, high uric acid, poor ECOG performance score, ≥65 years, metachronous metastasis, uncontrolled primary tumor are associated poor prognosis. LDH, uric acid, age, presence of metachron metastasis, controbility of primary tumor can be used as easy and inexpensive biomarkers to determine the prognosis and in the follow-up and treatment of patients with LNECs with brain metastases as metastases seen of other cancers.

References

  • 1. Fasano M, Corte Della CM, Papaccio F, Ciardielle F, Morgillo F. Pulmonary large-cell neuroendocrine carcinoma from epidemiology to therapy. J Thoroac Oncol. 2015;10: 1133-1141.
  • 2. Travis WD, Linnoila RI, Tsokos MG, et al. Neuroendocrine tumors of the lung with proposed criteria for large-cell neuroendocrine carcinoma. An ultrastructural, immunohistochemical, and flow cytometric study of 35 cases. Am J Surg Pathol. 1991;15(6): 529-53.
  • 3. Battafarano RJ, Fernanadez FG, Ritter j, et al. Large cell neuroendocrine carcinoma: an aggressive form of non-small cell lung cancer. J Thorac Cardiovasc surg. 2005;130:166-172.
Year 2023, Volume: 50 Issue: 1, 30 - 36, 19.03.2023
https://doi.org/10.5798/dicletip.1266706

Abstract

References

  • 1. Fasano M, Corte Della CM, Papaccio F, Ciardielle F, Morgillo F. Pulmonary large-cell neuroendocrine carcinoma from epidemiology to therapy. J Thoroac Oncol. 2015;10: 1133-1141.
  • 2. Travis WD, Linnoila RI, Tsokos MG, et al. Neuroendocrine tumors of the lung with proposed criteria for large-cell neuroendocrine carcinoma. An ultrastructural, immunohistochemical, and flow cytometric study of 35 cases. Am J Surg Pathol. 1991;15(6): 529-53.
  • 3. Battafarano RJ, Fernanadez FG, Ritter j, et al. Large cell neuroendocrine carcinoma: an aggressive form of non-small cell lung cancer. J Thorac Cardiovasc surg. 2005;130:166-172.
There are 3 citations in total.

Details

Primary Language Turkish
Subjects Health Care Administration
Journal Section Original Articles
Authors

Engin Kut This is me

Serkan Menekşe

Publication Date March 19, 2023
Submission Date October 25, 2022
Published in Issue Year 2023 Volume: 50 Issue: 1

Cite

APA Kut, E., & Menekşe, S. (2023). Brain Metastases, Large Cell Neuroendocrine Carcinomas and Prognosis. Dicle Tıp Dergisi, 50(1), 30-36. https://doi.org/10.5798/dicletip.1266706
AMA Kut E, Menekşe S. Brain Metastases, Large Cell Neuroendocrine Carcinomas and Prognosis. diclemedj. March 2023;50(1):30-36. doi:10.5798/dicletip.1266706
Chicago Kut, Engin, and Serkan Menekşe. “Brain Metastases, Large Cell Neuroendocrine Carcinomas and Prognosis”. Dicle Tıp Dergisi 50, no. 1 (March 2023): 30-36. https://doi.org/10.5798/dicletip.1266706.
EndNote Kut E, Menekşe S (March 1, 2023) Brain Metastases, Large Cell Neuroendocrine Carcinomas and Prognosis. Dicle Tıp Dergisi 50 1 30–36.
IEEE E. Kut and S. Menekşe, “Brain Metastases, Large Cell Neuroendocrine Carcinomas and Prognosis”, diclemedj, vol. 50, no. 1, pp. 30–36, 2023, doi: 10.5798/dicletip.1266706.
ISNAD Kut, Engin - Menekşe, Serkan. “Brain Metastases, Large Cell Neuroendocrine Carcinomas and Prognosis”. Dicle Tıp Dergisi 50/1 (March 2023), 30-36. https://doi.org/10.5798/dicletip.1266706.
JAMA Kut E, Menekşe S. Brain Metastases, Large Cell Neuroendocrine Carcinomas and Prognosis. diclemedj. 2023;50:30–36.
MLA Kut, Engin and Serkan Menekşe. “Brain Metastases, Large Cell Neuroendocrine Carcinomas and Prognosis”. Dicle Tıp Dergisi, vol. 50, no. 1, 2023, pp. 30-36, doi:10.5798/dicletip.1266706.
Vancouver Kut E, Menekşe S. Brain Metastases, Large Cell Neuroendocrine Carcinomas and Prognosis. diclemedj. 2023;50(1):30-6.